Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is more or less 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The current opinion among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price goal of $84.

The analysts priced targets range from a high of $101 to a low of sixty one dolars.

From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescribed drugs and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, healthcare relief abilities. The Corporate segment involves in offering administrative services and management. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.